[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Guardant Health Inc (GH)

Guardant Health Inc (GH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Guardant Health Earnings: Analysts Expect Another Loss, But Revenue Growth Tells a Different Story

Guardant Health reports second-quarter 2026 earnings after the close on July 30, with analysts expecting a loss of $0.74 per share on revenue of $314.2 million. The central question is whether the oncology testing company can sustain its recent revenue momentum while narrowing losses—a critical test for a growth story that has delivered mixed earnings surprises over the past year. With the stock trading well above its 200-day moving average but below recent highs, investors will be watching for signs that the path to profitability is accelerating.

Guardant Health is a precision oncology company that develops blood-based tests for cancer detection and monitoring,...

Fundamentals

See More
  • Market Capitalization, $K 19,103,684
  • Shares Outstanding, K 132,600
  • Annual Sales, $ 982,020 K
  • Annual Income, $ -416,280 K
  • EBIT $ -448 M
  • EBITDA $ -414 M
  • 60-Month Beta 1.59
  • Price/Sales 19.39
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 74.07% (+2.07%)
  • Historical Volatility 58.13%
  • IV Percentile 89%
  • IV Rank 73.46%
  • IV High 83.67% on 04/30/26
  • IV Low 47.50% on 08/13/25
  • Expected Move (DTE 22) 20.10 (13.27%)
  • Put/Call Vol Ratio 0.76
  • Today's Volume 449
  • Volume Avg (30-Day) 1,083
  • Put/Call OI Ratio 1.15
  • Today's Open Interest 20,822
  • Open Int (30-Day) 20,858
  • Expected Range 131.37 to 171.57

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 25 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.74
  • Number of Estimates 3
  • High Estimate $-0.70
  • Low Estimate $-0.79
  • Prior Year $-0.79
  • Growth Rate Est. (year over year) +6.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
140.86 +7.11%
on 07/29/26
174.08 -13.33%
on 07/06/26
+0.85 (+0.57%)
since 06/30/26
3-Month
85.64 +76.18%
on 05/01/26
174.08 -13.33%
on 07/06/26
+63.80 (+73.27%)
since 04/30/26
52-Week
40.35 +273.88%
on 08/01/25
174.08 -13.33%
on 07/06/26
+105.69 (+233.88%)
since 07/30/25

Most Recent Stories

More News
Guardant Health Earnings: Analysts Expect Another Loss, But Revenue Growth Tells a Different Story

Barchart Research What to Expect from GH Earnings GH Generated July 29, 2026 Current Price $144.16 EPS Estimate $$-0.74 Consensus Rating Strong Buy Average Move 10.12% Guardant Health Earnings: Analysts...

GH : 151.36 (+5.06%)
Guardant Health to Participate in Upcoming Investor Conferences

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences. Canaccord...

GH : 151.36 (+5.06%)
Guardant Health (GH) Q2 Earnings Report Preview: What To Look For

Guardant Health (GH) Q2 Earnings Report Preview: What To Look For

GH : 151.36 (+5.06%)
Actor and Cancer Advocate Patrick Dempsey Stars in Emotional Tribute Video From Guardant Health Memorializing Those Who Have Lost Their Lives to Colorectal Cancer

Dempsey is calling on Americans to prioritize getting screened and highlighting the innovative Shield blood test for CRC screening Guardant's Shield blood...

GH : 151.36 (+5.06%)
Guardant Health to Report Second Quarter 2026 Financial Results on July 30, 2026

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2026 after market close on Thursday, July 30, 2026. Company...

GH : 151.36 (+5.06%)
UnitedHealth Group Now Covers Guardant Health’s Shield Blood Test for Colorectal Cancer Screening

Updated United policy coverage from the largest commercial insurer in the U.S. means 100 million total covered lives have access to the FDA-approved Shield blood test for colorectal cancer (CRC) screening...

GH : 151.36 (+5.06%)
3 Mid-Cap Stocks We’re Skeptical Of

3 Mid-Cap Stocks We’re Skeptical Of

GH : 151.36 (+5.06%)
CSGP : 28.74 (-3.65%)
KEY : 22.53 (+1.58%)
Why Are Guardant Health (GH) Shares Soaring Today

Why Are Guardant Health (GH) Shares Soaring Today

GH : 151.36 (+5.06%)
Why Are Guardant Health (GH) Shares Soaring Today

Why Are Guardant Health (GH) Shares Soaring Today

GH : 151.36 (+5.06%)
3 Russell 2000 Stocks We Approach with Caution

3 Russell 2000 Stocks We Approach with Caution

GH : 151.36 (+5.06%)
SPB : 88.62 (+0.39%)
CRK : 12.30 (-2.46%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 50%. The market is indicating support for a bullish trend.

See More Share

Business Summary

Guardant Health Inc. is a precision oncology company. It focuses on conquer cancer through use of proprietary blood tests, vast data sets and advanced analytics. The company's Guardant Health Oncology Platform is designed for clinical development, regulatory and reimbursement to drive commercial adoption,...

See More

Key Turning Points

3rd Resistance Point 155.88
2nd Resistance Point 152.24
1st Resistance Point 148.15
Last Price 151.36
1st Support Level 140.42
2nd Support Level 136.78
3rd Support Level 132.69

See More

52-Week High 174.08
Last Price 151.36
Fibonacci 61.8% 123.00
Fibonacci 50% 107.22
Fibonacci 38.2% 91.44
52-Week Low 40.35

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.